Whereas FGF21 analogs have previously been tested in various DIO/DIO-MASLD mouse models [28], only a single efficacy study has so far been reported in a translational model of fibrosing MASH. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.